BofA lowered the firm’s price target on Albemarle to $146 from $156 and keeps a Buy rating on the shares. The firm has trimmed its 2024 EBITDA estimate to $1.1B from $1.25B, but increased its 2025 EBITDA to $1.96B from $1.8B.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
